• Journal of Radiation Protection and Research
• /
• 제33권3호
• /
• pp.93-97
• /
• 2008

The purpose of this study reported here was to investigate the ability of Bu-Zhong-Yi-Qi-Tang (BZYQT), known to elevate hematopoietic functions, to protect mice undergoing treatment with whole body single gamma-irradiation. BZYQT was given (25 mg/kg B.W.) intraperitoneally at 36 and 12 hours before irradiation and 30 minute and 24 hours after irradiation. Recovery of neutrophil and lymphocyte counts was significantly stimulated by extract of BZYQT. Stimulated recovery by the extract from the BZYQT was also observed in thrombocyte. However, the anti-radiation effect of erythrocyte, hemoglobin and hematocrit was not as significant as that of leukocyte. Further studies are needed to better characterize the protective nature of BZYQT extract and its ingredients.

• 대한수의학회지
• /
• 제43권3호
• /
• pp.323-331
• /
• 2003

We performed this study to determine the late biological effect of gamma radiation and effect of Bu-Zhong-Yi-Qi-Tang (BZYQT), a prescription of traditional Oriental medicine, on radiation-induced late biological effect (survival, hematological change, carcinogenesis) of mice irradiated with 3 Gy of gamma-radiation. There were little difference in body weights between normal and irradiated mice. Survival rate were decreased in irradiated mice and the survival rate and mean survival time of the groups treated with BZYQT were far better than the irradiation control group. A significant elevation of total leukocyte or lymphocyte counts was seen at week 4 and 12 of the group treated with BZYQT. Stimulated recovery by the extract from BZYQT was also observed in thrombocyte. Main gross findings of irradiated mice were appeared as enlargement of spleen, thymus and liver, tumorous nodules of lung and cyst or mass of ovary. Microscopically, there were various findings including hematopoietic and lymphoid tumor, lung cancer, ovarian cancer and cancer of other lesions. BZYQT reduced the incidence of tumor development. Further studies are needed to characterize better the protective nature of ingredients and active compounds.

• Integrative Medicine Research
• /
• 제6권3호
• /
• pp.317-324
• /
• 2017

Background: Bu-Zhong-Yi-Qi-Tang (BZYQT) has long been used for the treatment of severe weakness caused by general fatigue, loss of appetite, or indigestion. The aim of this feasibility study is to assess the effectiveness and safety of BZYQT for the treatment of functional dyspepsia (FD) with spleen qi deficiency. Methods: This study will be conducted at a single center as a prospective, nonrandomized, nonblinded, single-arm feasibility study. A total of 30 participants diagnosed with FD in accordance with the Rome III criteria will be enrolled. All patients will receive BZYQT for 4 weeks. The primary outcome is the change in the Nepean Dyspepsia Index-Korean version (NDI-K) scores between the baseline and 4-week images. The secondary outcomes include the tongue coating thickness, blood parameters, and BZYQT Questionnaire score. The NDI-K score will be acquired four times, at Weeks 0 (baseline), 2 (during treatment), 4 (after treatment), and 8 (after follow-up). Written informed consent will be obtained from all study participants prior to enrollment. This study has been approved by the Institutional Review Board of Kyung Hee University Korean Medicine Hospital. This study protocol is registered with the national clinical trial registry of the World Health Organization International Clinical Trials Registry Platform. Results will be published in a journal and will be disseminated both electronically and in print. Discussion: The results of this study may serve as a guide for researchers seeking to effectively evaluate the effects of BZYQT.

• Journal of Radiation Protection and Research
• /
• 제33권3호
• /
• pp.87-91
• /
• 2008

C57BL/6 마우스에서 자외선(Ultraviolet, UV) B 조사에 의한 표피 멜라닌세포의 변화에 대한 보중익기탕(Bu-Zhong-Yi-Qi-Tang, BZYQT)의 효과를 관찰하였다. 마우스에 UVB를 매일 $80\;mJ/cm^2$ (0.5 mW/sec)씩 7일간 조사하고, BZYQT를 UV 조사전 또는 조사 후에 복강내주사 또는 피부에 도포하여, 멜라닌세포 형성 억제효과 및 형성된 멜라닌세포에 대한 미백 효과를 dihydroxyphenylalanine (DOPA) 염색으로 관찰하였다. 마우스의 귀등쪽 표피를 분리하여 관찰한바, 정상대조군에서는 $mm^2$ 당 11-16개의 멜라닌세포가 관찰되었으며, UV 조사 일주일 후 발달된 가지를 가진 DOPA양성 멜라닌세포는 급격히 증가하였다. 멜라닌세포 형성 억제 실험에서는 평균치를 기준으로 복강 내 주사군에서 16.3%, 피부도포군에서 26.6%(p<0.01)의 효과가 관찰되었으며, 형성된 멜라닌세포의 감소 효과 실험에서는 평균치를 기준으로 복강 내 주사군의 경우 3주에 24.0%(p<0.01), 6주에 26.0%(p<0.01)의 효과가 관찰되었고, 피부도포군의 경우 3주에 5.2%, 6주에 12.5%(p<0.05)의 효과를 보였다. 이상의 결과는 BZYQT가 UV에 의한 멜라닌세포 형성 억제제 및 미백제로서의 적용 가능성을 제시하였다.

• 약학회지
• /
• 제52권1호
• /
• pp.7-11
• /
• 2008

A high performance liquid chromatographic (HPLC) method for the determination of glycyrrhizic acid was developed for the quality control of traditional herbal medicinal preparation Bu-Zhong-Yi-Qi-Tang (BZYQT), which is well-known herbal medicine used as tonic. RP-HPLC analysis was carried out using Capcell pak $C_{18}$ MG column $(5\;{\mu},\;150{\times}4.6\;mm)$ and a mobile phase consisting of acetonitrile and water containing 0.03% phosphoric acid (pH 2.46) at a flow rate of 1.0 ml/min. The optimum wavelength for the detection of the glycyrrhizic acid was found at 250 nm using diode-array UV/VIS detector. The glycyrrhizic acid in BZYQT shows good linearity $(r^2>0.999)$ in the range of $15\;{\mu}g/ml$ to 500 ${\mu}g/ml$. The limit of detection (LOD) was less than 5 ng and R.S.D for intra-day and inter-day reproducibility was less than 7%. The mean recovery of the glycyrrhizic acid was $97.3{\sim}113.0%$. These results suggest that the developed HPLC method is simple and efficient, and could be contributed for the quality control of commercial BZYQT products.

• 대한수의학회지
• /
• 제49권1호
• /
• pp.17-22
• /
• 2009

The effect of Bu-Zhong-Yi-Qi-Tang (BZYQT) on the changes of ultraviolet (UV) light B radiation-induced apoptotic sunburn cell (SBC) and epidermal ATPase-positive dendritic cell (DC) in SKH1- hr or ICR mouse were investigated. The mice were treated with UVB (200 mJ/$cm^2$) and were sacrificed 24 h later. BZYQT (50 mg/kg of body weight) or vehicle (saline) was given i.p. at 36 and 12 h before irradiation, and 30 min after irradiation or BZYQT cream (0.2%) or cream base (vehicle) was topically treated at 24 h and 15 min before irradiation, and immediately after irradiation. The skin of SKH1-hr mouse prepared from the back of untreated mice exhibited about 0.3 SBC/cm length of epidermis, and 24 h after UV irradiation, the applied areas show an increased number of SBCs. But the frequency of UVB-induced SBC formation was reduced by intraperitoneal injection of BZYQT extract (p < 0.01). The numbers of DC in normal ICR mouse were 628.00 ${\pm}$ 51.56 or 663.20 ${\pm}$ 62.58 per $mm^2$ of ear epidermis. By 1 day after UVB treatment, the number of ATPase-positive cells/$mm^2$ were decreased by 39.0% or 27.1% in i.p. or topical application group with vehicle. Treatment of BZYQT was associated with increase of 33.9% in i.p. group (p < 0.05) or 2.7% in topical application group in the number of ATPase positive cells compared with the irradiation control group. The results presented herein that BZYQT administration could reduce the extent of skin damages produced by UVB.